Advances in Key Drug Target Identification and New Drug Development for Tuberculosis

<div>New anti-TB drugs in clinical trials (a), the chemical structures of vasicoline, vasicolinone, vasicinone, vasicine, adhatodine, and anisotine (b), the chemical structures of BTZ-043, PBTZ-169, OPC-167832, and TBA-7371 (c), and the chemical structure of CPZEN-45 (d).</div>

BioMed Research International

fig1

Figure 1

Figure 1: Advances in Key Drug Target Identification and New Drug Development for Tuberculosis 